DB
ZNTL icon

Dmitry Balyasny’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Dmitry Balyasny’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,000
Closed -$1.08M – 3304
2022
Q3 		$1.08M Buy
+50,000
New +$1.37M ﹤0.01% 1763

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dmitry Balyasny's ZNTL Position: Q4 2025 in Review

Dmitry Balyasny sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 1,185,521 shares — an estimated $1.79M sold.

Dmitry Balyasny first reported a position in ZNTL in Q1 2023 and held it in 8 quarters. The position peaked at $1.79M in Q3 2025. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • Dmitry Balyasny reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 1,185,521 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $1.79M.
  • Dmitry Balyasny first reported a position in Zentalis Pharmaceuticals in Q1 2023 and held it in 8 quarters.
  • Dmitry Balyasny's Zentalis Pharmaceuticals position peaked at $1.79M in Q3 2025.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.